Clinical Research Protocols
For Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Compiled by Margaret Gross-King, RN, MS, OCN
Clinical Research Manager,
H. Lee Moffitt Cancer Center & Research Institute

This list of clinical research protocols relating to acute myelogenous leukemia and myelodysplastic syndrome is compiled for your convenience.

URCC-G2495, NCI-T95-00360, URCC-U6495M Phase II Study of Sequential TOPO and TOPO/VP-16 for Refractory or Relapsed Acute Myelogenous Leukemia (summary last modified 01/97).
Chairperson: Alex Yang-Chi Chang. Lead organization: University of Rochester Cancer Center. Age range: 15 and over.

MDA-DM-95131, NCI-T95-0061D Phase I Study of 9-AC as a 7-Day Continuous Infusion in Refractory Acute Leukemia and Blastic Phase Chronic Myelogenous Leukemia (summary last modified 01/97).
Chairperson: Hagop M. Kantarjian. Lead organization: University of Texas - M.D. Anderson Cancer Center. Age range: over 15.

MDA-DM-94109, NCI-T94-0157D Phase I Study of Pyrazine Diazohydroxide Administered on a 5-Day Bolus Schedule for Refractory Acute Leukemias and Blastic Phase Chronic Myelogenous Leukemia (summary last modified 05/96).
Chairperson: Susan Mary O’Brien. Lead organization: University of Texas - M.D. Anderson Cancer Center. Age range: over 15.

MDA-DM-94095, NCI-T94-0148C Phase I/II Randomized Study of TOPO/ARA-C vs TOPO/VP-16 vs VP-16/TOPO for Refractory Acute Myelogenous Leukemia (summary last modified 10/96).

JHOC-9446, NCI-T94-0196D Phase I Study of Phenylbutyrate for Myelodysplastic Syndrome and Relapsed Acute Myeloid Leukemia (summary last modified 03/97).

Chairperson: David A. Scheinberg. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 12 and over.

MVC-MCC-9409-2CC, NCI-V96-0966 Phase I Study of Deoxycytidine Chemoprotection With High- Dose Cytarabine in Refractory Acute Myelogenous Leukemia and Other Hematologic Malignancies (summary last modified 10/96).
Chairperson: Steven Grant. Lead organization: Massey Cancer Center, Medical College of Virginia. Age range: 18 and over.

SWOG-S9617, SWOG-96167 Phase I Study of Mitoxantrone/Etoposide/PSC 833 in Patients 56 Years of Age and Over With Previously Untreated Acute Myeloid Leukemia (summary last modified 02/97).

Chairperson: Joseph G. Jurcic. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: no age specified.

CWRU-ICC-2994, NCI-T94-0078D Phase I Study of Sequential Topotecan and VP-16 for Relapsed/Refractory Acute Myelogenous and Lymphocytic Leukemias and for Blastic Phase Chronic Myelogenous Leukemia (summary last modified 08/96).
Chairperson: Brenda W. Cooper. Lead organization: Case Western Reserve University/Ireland Cancer Center. Age range: over 18.

FHCRC-1008.00, NCI-H96-0922 Phase I Pilot Study of High-Dose Chemotherapy and Interleukin-2- Incubated Peripheral Blood Stem Cells Followed by Additional Interleukin-2 Therapy for Acute Myelogenous Leukemia (summary last modified 06/97).
Chairperson: Leona Holmberg. Lead organization: Fred Hutchinson Cancer Research Center. Age range: 60 and under.

MSKCC-93161, NCI-H94-0460 Phase II Study of PBSC Rescue Following Myeloablative TBI/VP-16 for Acute Leukemia (summary last modified 12/94).
Chairperson: Peter Maslak. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 16 to 65.

Chairperson: Peter Maslak. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

CLB-9620 Phase II Study of Autologous Stem Cell Transplantation Following ARA-C/VP-16 and BU/VP-16 for Acute Myeloid Leukemia in Second Remission (summary last modified 12/96).

Chairperson: Charles A. Linker. Lead organization: Cancer and Leukemia Group B. Age range: 15 to 59.

MSKCC-92103A2, NCI-H92-0143 Phase II Study of BU/CTX Cytoreduction of Acute and Chronic Leukemias and Myelodysplastic Syndromes in Patients Undergoing Allogeneic Bone Marrow Transplantation (summary last modified 05/96).

Chairperson: Esperanza B. Papadopoulos. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: under 50 or special approval.

MSKCC-93045, NCI-H93-0293 Phase III Randomized Study of Unmodified vs T-Cell-Depleted, Allogeneic, HLA-Identical Bone Marrow Transplantation in Patients With Acute Leukemia in First or Second Remission (summary last modified 06/95).

Chairperson: Farid Boulad. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 5 to 55 preferred.

FHCRC-600.02, NCI-H95-0674 Phase I/II Pilot Study of G-CSF-Stimulated Donor Peripheral Blood Mononuclear Cells for Post-Transplant Relapse of Hematologic Malignancies (summary last modified 02/97).


FHCRC-964.00, NCI-V96-0921 Phase II Trial of Induction and Consolidation With Idarubicin and Cytarabine With G-CSF Followed by Myeloablative Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Myelodysplasia and Secondary Acute Myeloid Leukemia (summary last modified 03/97).


RPCI-DS-96-48, NCI-G97-1152 Phase III Study of High Dose Cytarabine and Idarubicin Induction, High-Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Acute Myeloid Leukemia (AML) (summary last modified 05/97).


NCI-96-C-0064F, NCI-T95-0042N Phase I Study of the Immunotoxin LMB-2 in Tac-Expressing Leukemias and Lymphomas (summary last modified 05/97).

Chairperson: Robert Kreitman. Lead organization: Laboratory of Molecular Biology. Age range: 18 and over.

MDA-DM-94078, NCI-G96-1001 Phase II Study of Filgrastim-Stimulated HLA Identical Allogeneic Peripheral Blood Stem Cells for Patients With High-Risk Acute Myelogenous Leukemia or CML in Blast Crisis (summary last modified 06/97).

Chairperson: Sergio Giralt. Lead organization: University of Texas - M.D. Anderson Cancer Center. Age range: 55 to 70.

CLB-9420 Phase I Study of Induction and Post-Remission Therapy With ADE (Cytarabine/Daunorubicin/Etoposide) or ADEP (ADE Plus PSC 833) Followed by IL-2 for Patients Age 60 and Over With Acute Myeloid Leukemia (summary last modified 07/97).

Chairperson: Edward James Lee. Lead organization: Cancer and Leukemia Group B. Age range: 60 and over.

MSKCC-89119A5, NCI-H89-0254 Phase II Study of T-Cell Depleted Allogeneic Bone Marrow Transplantation for Acute and Chronic Leukemias and Preleukemia/Myelodysplastic Syndromes (summary last modified 02/97).

Chairperson: James William Young. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: under 55 or special approval.

SWOG-9126 Phase III Randomized Study of ARA-C/DNR With vs Without the Drug Resistance Inhibitor CYSP in High-Risk Patients With AML (summary last modified 04/96).

Chairperson: Alan Francis List. Lead organization: Southwest Oncology Group. Age range: 18 to 70.

CLB-9621 Phase I Study of MDR Modulation With PSC-833 With a Pilot Study of Cytogenetic Risk Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy With rIL-2 in Previously Untreated Patients With Acute Myelogenous Leukemia (AML) and Less Than 60 Years Old (summary last modified 07/97).

Chairperson: Jonathan Eliahu Kolitz. Lead organization: Cancer and Leukemia Group B. Age range: 15-60.

SWOG-9333 Phase III Randomized Study of ARA-C/DNR vs DHAD/VP-16 Induction Therapy Followed by ARA-C/DNR Consolidation Therapy in Older Patients With Previously Untreated Acute Myeloid Leukemia (summary last modified 10/96).

Chairperson: Jeanne E. Anderson. Lead organization: Southwest Oncology Group. Age range: 56 and over.

**Myelodysplastic Syndrome**

UW-26-245-B, NCI-V96-0848 Phase I Trial of Subcutaneous Outpatient Interleukin-2 for Patients With Myelodysplastic Syndrome (summary last modified 04/97).

Chairperson: Philip Gold. Lead organization: University of Washington Medical Center. Age range: 15 and over.
IUMC-951023, NCI-T95-0088O Phase II Study of Interleukin-2 for Myelodysplastic Syndromes (summary last modified 02/97).

Chairperson: Michael Steven Gordon. Lead organization: Indiana University Cancer Center. Age range: 18 and over.

MDA-DM-95033, NCI-T95-0079D Phase II Study of TOPO/ARA-C in Myelodysplastic Syndrome (summary last modified 08/96).


JHOC-9446, NCI-T94-0196D Phase I Study of Phenylbutyrate for Myelodysplastic Syndrome and Relapsed Acute Myeloid Leukemia (summary last modified 03/97).


DFCI-96278, NCI-T96-0112 Phase II Study of All-Trans Retinoic Acid (Tretinoin) and Bryostatin 1 in Patients With Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes (summary last modified 07/97).


SPARTA-RII-9601, NCI-V96-1069 Phase I/II Study of N-(4-Carboxyphenyl) Retinamide for Refractory Anemia or Refractory Anemia With Ringed Sideroblasts (summary last modified 06/97).

Chairperson: Edgar M. Moran. Lead organization: Sparta Pharmaceuticals, Inc. Age range: 18 and over.

E-3996 Phase II Study of GM-CSF With Intermediate-Dose Cytarabine and Mitoxantrone in High-Risk Myelodysplastic Syndrome (summary last modified 08/97).

Chairperson: John M. Bennett. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

WSU-D-696-87, NCI-V93-0345 Phase II Study of Allogeneic or Syngeneic Bone Marrow Transplantation Following Cytoreduction With BU/CTX for Low-Risk and BU/ARA-C/CTX for High-Risk Acute Nonlymphocytic Leukemia, Myelodysplastic Syndromes, and Secondary Acute Myeloid Leukemia (summary last modified 06/95).

Chairperson: Chatchada Karanes. Lead organization: Barbara Ann Karmanos Cancer Institute. Age range: 60 and under.

EORTC-06962 Phase III Randomized Study to Assess Intensification of the Conditioning Regimen for Allogeneic Stem Cell Transplantation for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse (summary last modified 08/97).


EORTC-58921 Phase III Randomized Comparison of IDA vs DHAD Combined With ARA-C/VP-16 for Induction and Combined With High-Dose ARA-C for Intensification in Children With Newly Diagnosed AML or Myelodysplastic Syndrome (summary last modified 06/93).


EORTC-06961 Phase III Randomized Comparison of Autologous Peripheral Blood Stem Cell Transplantation vs Second Intensive Consolidation With High-Dose Cytarabine Following Common Induction and Consolidation in Patients With Poor Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (sAML) to MDS of More Than 6 Months Duration (summary last modified 08/97).


CCG-2891 Phase III Randomized Study of Intensive Schedule vs Standard Schedule Induction Chemotherapy With DNR/ARA-C/ VP-16/TG/DM and of Autologous BMT vs Combination Chemotherapy for Intensification in Children With ANLL or Myelodysplastic Syndrome (summary last modified 09/95).


CCG-2961 Phase III Randomized Study for Untreated Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Intensively-Timed Induction Chemotherapy, Followed by Consolidation With the Same Chemotherapy vs Fludarabine/Cytarabine/Idarubicin, Followed by Intensification Either With High-Dose Cytarabine/Asparaginase With vs Without Subsequent IL-2 or With AlBMT (summary last modified 08/97).


Legend for abbreviations:
CCG = Children’s Cancer Study Group
CLB = Cancer & Leukemia Group B
CWRU = Case Western Reserve University
DFCI = Dana-Farber Cancer Institute
E = Eastern Cooperative Oncology Group
EORTC = European Organization for Research on Treatment of Cancer
FHRC = Fred Hutchinson Cancer Research Center
IUMC = Indiana University Medical Center
JHOC = Johns Hopkins Oncology Center
MCV = Medical College of Virginia
MDA = M.D. Anderson Cancer Center
MSKCC = Memorial Sloan-Kettering Cancer Center
RPCI = Roswell Park Cancer Institute
SPARTA = Sparta Pharmaceuticals, Inc.
SWOG = Southwest Oncology Group
URCC = University of Rochester Cancer Center
UW = University of Washington
WSU = Wayne State University